New therapy for pancreatic cancer patients shows promising results
Friday, June 6, 2014 - 02:31
in Health & Medicine
A new drug called MM-398, given in combination with 5-flourouracil and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer, a new clinical trial has demonstrated. The NAPOLI-1 (NAnoliPOsomaL Irinotecan) Phase 3 study -- a final confirmation of a drug's safety and effectiveness -- was conducted among patients with metastatic pancreatic cancer who previously received gemcitibine, which has been the standard-of-care therapy for such patients.